MARSEILLE, France, Dec. 02, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Firm”) at the moment launched its 2021 monetary calendar:
|March 18, 2021:||Publication of 2020 monetary statements|
|Might 11, 2021:||Publication of income for 1Q2021|
|Might 28, 2021:||Annual Normal Shareholders Assembly|
|September 15, 2021:||Publication of half yr monetary statements|
|November 16, 2021:||Publication of income for 3Q2021|
All monetary stories are launched earlier than market open CET.
All company data, such because the Firm’s monetary statements and company shows, is obtainable on https://investors.innate-pharma.com.
About Innate Pharma:
Innate Pharma S.A. is a industrial stage oncology-focused biotech firm devoted to bettering therapy and scientific outcomes for sufferers by way of therapeutic antibodies that harness the immune system to battle most cancers.
Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca within the US, EU and Switzerland, was authorised by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for bushy cell leukemia. Innate Pharma’s broad pipeline of antibodies consists of a number of doubtlessly first-in-class scientific and preclinical candidates in cancers with excessive unmet medical want.
Innate has been a pioneer within the understanding of pure killer cell biology and has expanded its experience within the tumor microenvironment and tumor-antigens, in addition to antibody engineering. This revolutionary method has resulted in a diversified proprietary portfolio and main alliances with leaders within the biopharmaceutical business together with Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.
Based mostly in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq within the US.
Study extra about Innate Pharma at www.innate-pharma.com
Details about Innate Pharma shares:
Euronext: IPH Nasdaq: IPHA
Disclaimer on forward-looking data and danger components:
This press launch incorporates sure forward-looking statements, together with these throughout the which means of the Personal Securities Litigation Reform Act of 1995.Using sure phrases, together with “consider,” “potential,” “count on” and “will” and comparable expressions, is meant to establish forward-looking statements. Though the corporate believes its expectations are primarily based on affordable assumptions, these forward-looking statements are topic to quite a few dangers and uncertainties, which might trigger precise outcomes to vary materially from these anticipated. These dangers and uncertainties embrace, amongst different issues, the uncertainties inherent in analysis and growth, together with associated to security, development of and outcomes from its ongoing and deliberate scientific trials and preclinical research, evaluation and approvals by regulatory authorities of its product candidates, the Firm’s commercialization efforts, the Firm’s continued means to lift capital to fund its growth and the general affect of the COVID-19 outbreak on the worldwide healthcare system in addition to the Firm’s enterprise, monetary situation and outcomes of operations. For an extra dialogue of dangers and uncertainties which might trigger the corporate’s precise outcomes, monetary situation, efficiency or achievements to vary from these contained within the forward-looking statements, please discuss with the Danger Components (“Facteurs de Risque”) part of the Common Registration Doc filed with the French Monetary Markets Authority (“AMF”), which is obtainable on the AMF web site http://www.amf-france.org or on Innate Pharma’s website, and public filings and stories filed with the U.S. Securities and Trade Fee (“SEC”), together with the Firm’s Annual Report on Type 20-F for the yr ended December 31, 2019, and subsequent filings and stories filed with the AMF or SEC, or in any other case made public, by the Firm. This press launch and the data contained herein don’t represent a proposal to promote or a solicitation of a proposal to purchase or subscribe to shares in Innate Pharma in any nation.
For added data, please contact: